New treatment for children and young adults with a brain tumor
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new treatment approach for a rare brain tumor called NGGCT. It aims to see if a different way of treating the tumor can be effective and safe for children and young adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 30 years old.
- You must have a newly diagnosed NGGCT in a specific area of the brain (the suprasellar or pineal region).
- Your tumor must have certain markers found in blood or spinal fluid, or specific types of tumor cells seen under a microscope.
- You must meet certain blood count and organ function levels before starting treatment.
- You must not have received any prior treatment for this tumor other than surgery and steroids.
- You must be able to speak English, Spanish, or French, unless you are willing to skip the quality of life assessments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “molecular” (DNA-related) features of germ cell tumors in children and teens. It also follows patients over time, which can help researchers understand tumor patterns and improve future care.
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Hear when a new Central Nervous System Nongerminomatous Germ Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.